2. Academic Validation
  3. Statin-mediated disruption of Rho GTPase prenylation and activity inhibits respiratory syncytial virus infection

Statin-mediated disruption of Rho GTPase prenylation and activity inhibits respiratory syncytial virus infection

  • Commun Biol. 2021 Oct 29;4(1):1239. doi: 10.1038/s42003-021-02754-2.
Manpreet Malhi 1 2,  Michael J Norris 3 4,  Wenming Duan 4,  Theo J Moraes 3 4 5,  Jason T Maynes 6 7 8
Affiliations

Affiliations

  • 1 Department of Biochemistry, University of Toronto, Toronto, ON, Canada.
  • 2 Program in Molecular Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
  • 3 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • 4 Program in Translational Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
  • 5 Department of Paediatrics, Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
  • 6 Department of Biochemistry, University of Toronto, Toronto, ON, Canada. [email protected].
  • 7 Program in Molecular Medicine, The Hospital for Sick Children, Toronto, ON, Canada. [email protected].
  • 8 Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada. [email protected].
PMID: 34716403 DOI: 10.1038/s42003-021-02754-2
Abstract

Respiratory syncytial virus (RSV) is a leading cause of severe respiratory tract infections in children. To uncover new Antiviral therapies, we developed a live cell-based high content screening approach for rapid identification of RSV inhibitors and characterized five drug classes which inhibit the virus. Among the molecular targets for each hit, there was a strong functional enrichment in lipid metabolic pathways. Modulation of lipid metabolites by statins, a key hit from our screen, decreases the production of infectious virus through a combination of Cholesterol and isoprenoid-mediated effects. Notably, RSV Infection globally upregulates host protein prenylation, including the prenylation of Rho GTPases. Treatment by statins or perillyl alcohol, a geranylgeranyltransferase inhibitor, reduces Infection in vitro. Of the Rho GTPases assayed in our study, a loss in Rac1 activity strongly inhibits the virus through a decrease in F protein surface expression. Our findings provide new insight into the importance of host lipid metabolism to RSV Infection and highlight geranylgeranyltransferases as an Antiviral target for therapeutic development.

Figures
Products